meganuclease

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – French firm Cellectis and North Carolina-based Precision Biosciences have filed two new suits against each other alleging infringement of US patents covering modified meganucleases.

Helix will promote Cellectis' Genome Positioning System line of products and services in India.

The French firm gains access to Cyto Pulse's electroporation technologies and equipment.

Cedarlane will distribute Cellectis Bioresearch's kits in Canada.

The patent has been the subject of ongoing litigation between the French and US biotech firms.

The agricultural products company will use Cellectis' meganuclease tools and will invest in the French firm.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.